Home › Phases › Phase 1

Phase 1 (173 companies)

Companies with at least one active program at Phase 1.

Ticker Company Therapeutic areas Phase 1 programs Lead stage Mkt cap Programs
ABSI Absci DermatologyGI/Hepatology+1 3 Phase 1 $1.31B 6
ACIU AC Immune Neurology Rare 5 Phase 3 $210M 11
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 3 Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 3 Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology 2 Phase 2 $15.2M 4
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 $16.6M 4
ADAG Adagene Oncology 4 Phase 2 $99.4M 10
ACET Adicet Bio ImmunologyNeurology+2 Rare 7 Phase 1 $26.0M 8
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 2 Approved $1.79B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved $111M 10
AKTS Aktis Oncology Oncology 10 Phase 1 $910M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 1 NDA Submitted $41.9M 5
ALLO Allogene Therapeutics ImmunologyOncology Rare 5 Phase 2 $256M 10
DRTS Alpha Tau Medical Oncology 1 Phase 2 $1.12B 6
ALMS Alumis DermatologyImmunology+1 1 Phase 3 $628M 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 3 Phase 2 $161M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 3 Approved $1.36B 9
ANIX Anixa Biosciences Oncology 2 Phase 1 $92.8M 3
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 $662M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 5 Phase 2 — 9
APVO Aptevo Therapeutics Oncology 2 Phase 1 $1.6M 8
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.36B 8
AVBP ArriVent BioPharma Oncology 4 Phase 3 $553M 7
ARTV Artiva Biotherapeutics Oncology 1 Phase 1 $191M 6
ARVN Arvinas NeurologyOncology Rare 7 Approved $447M 10
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 9 Approved $290M 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 4 Phase 2 $2.14B 6
BCAX Bicara Therapeutics Oncology 3 Phase 2 $637M 4
BCYC Bicycle Therapeutics Oncology 1 Phase 2 $224M 4
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 1 Approved $1.93B 4
BMEA Biomea Fusion MetabolicOncology 2 Phase 2 $35.5M 4
BDTX Black Diamond Therapeutics Oncology 1 Phase 2 $82.8M 4
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $30.7M 8
BBOT BridgeBio Oncology Therapeutics Oncology 6 Phase 1 $156M 6
CCCC C4 Therapeutics Oncology 1 Phase 2 $332M 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare 8 Phase 2 $220M 8
CAMP Camp4 Therapeutics — 1 Phase 1 $251M 1
CADL Candel Therapeutics Oncology 1 Phase 3 $424M 4
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $489M 2
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 2 Phase 3 $187M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 $2.20B 6
CLRB Cellectar Biosciences Oncology 2 Phase 2 $9.2M 7
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 4 Phase 1 $249M 9
CLYM Climb Bio HematologyImmunology+1 Rare 5 Phase 2 $574M 8
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $4.85B 7
CHRS Coherus Oncology Oncology 2 Approved $74.0M 5
CMPX Compass Therapeutics Oncology 13 Phase 2 $109M 15
CGEN Compugen Oncology 2 Phase 3 $191M 7
CTNM Contineum Therapeutics NeurologyRespiratory Rare 1 Phase 2 $375M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
COYA Coya Therapeutics Neurology Rare 1 Phase 2 $70.8M 6
CBIO Crescent Biopharma Oncology 9 Phase 2 $507M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved — 6
CUE Cue Biopharma ImmunologyOncology 3 Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 6 NDA Submitted $602M 10
CTMX CytomX Therapeutics Oncology 6 Phase 1 $423M 7
DBVT DBV Technologies Immunology 1 NDA Submitted $3.14B 2
IRON Disc Medicine GI/HepatologyHematology+2 Rare 3 Phase 3 $3.49B 9
EIKN Eikon Therapeutics Oncology 10 Phase 2 $279M 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 1 Phase 2 $167M 3
ELTX Elicio Therapeutics Oncology 2 Phase 2 $40.5M 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 3 Phase 2 $48.0M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 2 Approved $253M 8
ELVN Enliven Therapeutics Oncology 1 Phase 1 $3.45B 1
ERAS Erasca Oncology 2 Phase 1 $4.87B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.84B 17
EXEL Exelixis CardiovascularOncology 7 Approved $16.7B 23
FATE Fate Therapeutics ImmunologyOncology+1 Rare 6 Phase 2 $124M 10
FBRX Forte Biosciences DermatologyGI/Hepatology 2 Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+4 Rare 3 Approved $61.4M 16
GANX Gain Therapeutics MetabolicNeurology Rare 1 Phase 1 $52.5M 5
GNLX Genelux Oncology 1 Phase 3 $96.1M 3
GHRS GH Research NeurologyWomen's Health 1 Phase 2 $1.25B 4
HRMY Harmony Biosciences MetabolicNeurology Rare 2 Approved $1.94B 17
IDYA IDEAYA Biosciences Oncology 12 NDA Submitted $2.65B 15
IMTX Immatics Oncology 7 Phase 3 $958M 8
IMMX Immix Biopharma Hematology Rare 1 Phase 1 $603M 1
IMRX Immuneering Oncology 4 Phase 3 $224M 5
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $116M 4
IBRX ImmunityBio Infectious DiseaseOncology 4 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 8 Approved $1.44B 12
IMNM Immunome Oncology Rare 6 NDA Submitted $2.03B 9
INAB IN8bio ImmunologyOncology 3 Phase 1 $8.9M 4
INBX Inhibrx Biosciences Oncology 3 NDA Submitted $1.10B 6
INSM Insmed CardiovascularImmunology+3 Rare 7 Approved $26.7B 15
IVVD Invivyd Infectious Disease 1 Approved $152M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 2 Approved $4.49B 29
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 $1.07B 4
JANX Janux Therapeutics Oncology 4 Phase 1 $655M 4
KAPA Kairos Pharma Oncology 1 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 2 Phase 2 $60.7M 13
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $222M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare 1 Phase 3 $4.1M 4
KURA Kura Oncology MetabolicOncology 8 Approved $688M 13
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 2 Phase 2 $10.4B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.30B 3
LEGN Legend Biotech Oncology Rare 16 Approved $3.12B 17
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 2 Phase 2 $236M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 2 Phase 2 $207M 13
LQDA Liquidia CardiovascularImmunology+1 Rare 4 Approved $5.11B 9
MAIA MAIA Biotechnology Oncology 1 Phase 3 $77.2M 8
MRKR Marker Therapeutics Oncology 4 Phase 1 $14.0M 5
MAZE Maze Therapeutics MetabolicRenal Rare 1 Phase 2 $1.80B 4
MBX MBX Biosciences Metabolic Rare 1 Phase 3 $2.64B 4
MDNAF Medicenna Therapeutics Oncology 2 Phase 2 $14.8M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 3 Phase 3 $827M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 2 Approved $1.54B 5
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 $47.7M 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 4 Phase 2 $775M 7
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
NKTX Nkarta ImmunologyNeurology+1 Rare 8 Phase 1 $89.6M 8
NBP NovaBridge Biosciences OncologyOphthalmology 4 Phase 2 $95.4M 7
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 8 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 6 Phase 3 $660M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare 4 Phase 3 $257M 12
OLMA Olema Pharmaceuticals Oncology 2 Phase 3 $633M 3
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.04B 6
ONCY Oncolytics Biotech Oncology 1 Phase 2 $51.7M 4
IRD Opus Genetics Ophthalmology Rare 2 Approved $391M 12
ORIC Oric Pharmaceuticals Oncology 2 Phase 3 $831M 5
OVID Ovid Therapeutics Neurology Rare 1 Phase 2 $419M 4
PALI Palisade Bio Immunology 1 Phase 2 $181M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 $16.0M 4
CATX Perspective Therapeutics Oncology 4 Phase 1 $104M 5
PHIO Phio Pharmaceuticals Oncology 3 Phase 1 $8.6M 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 4 Phase 1 $197M 5
PRLD Prelude Therapeutics HematologyOncology Rare 3 Phase 1 $266M 3
PRME Prime Medicine GI/HepatologyRespiratory Rare 2 Phase 1 $699M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 3 Phase 2 $4.8M 7
PMN ProMIS Neurosciences Neurology Rare 1 Phase 1 $28.9M 9
PRQR ProQR Therapeutics MetabolicNeurology Rare 2 Phase 1 $163M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 2 Approved $8.14B 12
RXRX Recursion Pharmaceuticals Oncology 2 Phase 2 $1.69B 6
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $3.64B 4
RVMD Revolution Medicines Oncology 2 Approved $35.2B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved $8.08B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 2 Approved $236M 4
SGMT Sagimet Biosciences DermatologyMetabolic 1 Phase 3 $709M 3
SANA Sana Biotechnology MetabolicOncology 1 Phase 1 $563M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 5 Approved $1.58B 11
SCYX Scynexis Infectious DiseaseRenal Rare 3 Approved $28.4M 5
SEPN Septerna ImmunologyMetabolic+1 Rare 2 Phase 1 $1.90B 5
SION Sionna Therapeutics Respiratory Rare 4 Phase 2 $139M 5
SLDB Solid Biosciences CardiovascularNeurology Rare 2 Phase 3 $695M 6
STOK Stoke Therapeutics Neurology Rare 1 Phase 3 $1.73B 2
GPCR Structure Therapeutics MetabolicRespiratory Rare 2 Phase 3 $3.90B 5
STRO Sutro Biopharma Oncology 2 Phase 1 $148M 3
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $822M 7
TNGX Tango Therapeutics Oncology 5 Phase 1 $3.75B 5
TECX Tectonic Therapeutic Cardiovascular Rare 2 Phase 2 $401M 4
TLX Telix Pharmaceuticals Oncology 7 Approved $3.01B 25
TGTX Tg Therapeutics Neurology Rare 2 Approved $9.48B 6
HURA TuHURA Biosciences Oncology 3 Phase 3 $92.1M 4
TYRA Tyra Biosciences MetabolicOncology Rare 2 Phase 2 $1.35B 5
UNCY Unicycive Therapeutics Renal 1 NDA Submitted $108M 2
QURE uniQure HematologyMetabolic+1 Rare 2 Approved $1.46B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 3 Approved $230M 27
PCVX Vaxcyte Infectious Disease 2 Phase 3 $9.40B 7
VKTX Viking Therapeutics MetabolicNeurology Rare 3 Phase 3 $3.43B 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare 4 Phase 3 $1.58B 6
VRDN Viridian Therapeutics ImmunologyOphthalmology 2 Approved $3.41B 7
VYGR Voyager Therapeutics MetabolicNeurology Rare 2 Phase 1 $94.6M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 1 Phase 3 $69.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 3 Phase 2 $560M 5
XNCR Xencor ImmunologyNeurology+1 Rare 21 Approved $2.59B 28
XENE Xenon Pharmaceuticals Neurology Rare 4 NDA Submitted $3.81B 9
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted $1.88B 11
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 $99.7M 4
ZYME Zymeworks OncologyRespiratory 5 Approved $1.78B 12